Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial

@inproceedings{Tricoci2015InfusionOR,
  title={Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial},
  author={Pierluigi Tricoci and Denise M. D’Andrea and Paul A Gurbel and Zhenling Yao and Marina A Cuchel and Brion M Winston and Robert J. Schott and Robert Jason Weiss and Michael A. Blazing and Louis Cannon and Alison Bailey and Dominick Joseph Angiolillo and Andreas Gille and Charles L. Shear and Samuel D. Wright and John Hunter Alexander},
  booktitle={Journal of the American Heart Association},
  year={2015}
}
BACKGROUND CSL112 is a new formulation of human apolipoprotein A-I (apoA-I) being developed to reduce cardiovascular events following acute coronary syndrome. This phase 2a, randomized, double-blind, multicenter, dose-ranging trial represents the first clinical investigation to assess the safety and pharmacokinetics/pharmacodynamics of a CSL112 infusion among patients with stable atherosclerotic disease. METHODS AND RESULTS Patients were randomized to single ascending doses of CSL112 (1.7, 3… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Acute renal failure associated with immunoglobulin therapy.

American journal of kidney diseases : the official journal of the National Kidney Foundation • 1995
View 9 Excerpts
Highly Influenced

Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial

JC Tardif, J Gr egoire, +9 authors J Rod es-Cabau
2007
View 3 Excerpts
Highly Influenced

HDL cholesterol efflux capacity is inversely associated with incident CHD events independent of HDL-C and ApoA-I concentrations

D Saleheen, R Scott, +10 authors DJ. Rader
Circulation. 2014;130:A19753. Presented at: American Heart Association Scientific Sessions • 2014
View 1 Excerpt

Similar Papers

Loading similar papers…